Hair Loss Drugs: Alopecia Areata and Androgenetic Alopecia

As of 2026-11-14, Lilly’s Olumiant, Pfizer’s Litfulo and India’s Sun Pharma Leqselvi had US alopecia areata approvals; AnHorn’s AH-001 belongs to the separate AGA development field.

Lilly reported on 2026-09-25 that 42% on Olumiant 4 mg versus 5% on placebo reached SALT ≤20 at Week 36 in adolescent alopecia areata.

Nektar said on 2026-11-12 that its rezpegaldesleukin AA Phase 3 was planned to begin in December 2026; initiation and design are the next test beyond JAK inhibition.

Hair Loss Drugs: Alopecia Areata and Androgenetic Alopecia

Alopecia areata (AA) is immune-mediated; androgenetic alopecia (AGA) involves androgen signaling. The two populations are grouped separately and their hair outcomes are not interchangeable.

Competitive landscape

AssetCompanyMechanism / routeStageIndicationTrial identifierDealLatest developmentSource
Olumiant / baricitinibEli LillyUSJAK1/2 inhibitorOralUS approvedAA; age 12+——Adolescent Week 36 SALT ≤20: 42% with 4 mglilly.gcs-web.compi.lilly.com
Litfulo / ritlecitinibPfizerUSJAK3 / TEC-family inhibitorOralUS approvedSevere AA; age 12+——FDA pivotal evidence: 718 patientsfda.gov
Leqselvi / deuruxolitinibSun PharmaIndiaJAK inhibitorOralUS approvedAdult severe AA——FDA original approval 2024-07-25; approval is distinct from supplyfda.gov
rezpegaldesleukinNektarUSIL-2 / regulatory T-cell pathwaySubcutaneousPost-Phase 2 AA; Phase 3 plannedAA——AA Phase 3 planned December 2026; distinct from AD Phase 3prnewswire.com
AH-001AnHorn MedicinesTaiwanAR protein degradationTopicalUS Phase 1 completion announcedAGA——Phase 1 completed per 2025-10-30 release; Phase 2 efficacy testing next, no date verifiedanhornmed.com
GT20029Kintor PharmaChinaAR protein degradationTopicalHistorical Phase 2 results reportedAGA——Positive Phase 2 release dated 2024-04-21; current stage not inferreden.kintor.com.cn
JSONCSV

Taiwan and Asia

Taiwan’s AnHorn announced US Phase 1 completion for topical AR degrader AH-001 on 2025-10-30; safety findings do not establish hair-growth efficacy. China’s Kintor reported positive AGA Phase 2 results for GT20029 on 2024-04-21; this is dated historical evidence, without an assumed Phase 3 outcome. India’s Sun Pharma has an approved AA drug, a different indication.